News

­

Alectos Announces Preclinical Results in TAPP Mouse Model of Alzheimer’s Disease

Oct 26, 2014 – Alectos today announced publication of preclinical studies showing that pharmacological inhibition of O-GlcNAcase (OGA) prevents cognitive decline and amyloid plaque formation in the TAPP mouse model of Alzheimer’s disease. For details, see: Yuzwa, S.A. et al. Mol Neurodegener 9:42 (2014).

October 26th, 2014|Tags: , , , , , , , |

Alectos Supports NSERC Funding for Prof. M.J. Boulanger at UVic

Oct 6, 2014 – Alectos today announced its support for NSERC funding for the group of Prof. M.J. Boulanger at the University of Victoria, Department of Biochemistry & Microbiology, in a project titled “Cloning and expression of human glucocerebrosidase”. Parkinson’s disease (PD) is a worldwide health problem that is characterized by the buildup of abnormal [...]

October 6th, 2014|Tags: , , , , |

Alectos Announces Preclinical Data for Novel Cancer Metabolism Target

May 22, 2014 – Alectos today announced publication of preclinical studies showing that both knockdown and pharmacological inhibition of O-GlcNAc transferase (OGT) result in reduced metabolic output, increased apoptosis, and impaired survival in tumor cells.  This data strongly supports OGT as a novel cancer metabolism target. For details, see: Ferrer, C.M. et al. Mol Cell [...]

May 22nd, 2014|Tags: , , , |

Alectos Therapeutics Announces Achievement of Preclinical Milestone in Merck Alzheimer’s Collaboration

Vancouver, British Columbia (November 16, 2012) – Alectos Therapeutics Inc. today announced the achievement of a preclinical milestone in its research collaboration with Merck, known as MSD outside the U.S. and Canada, to identify and develop compounds that modulate O-linked N-acetylglucosaminidase (OGA), an enzyme that is believed to be involved in the development of Alzheimer’s [...]

November 16th, 2012|Tags: , , , |

Alectos Supports NSERC Funding for Prof. B.M. Pinto at SFU

July 16, 2012 – Alectos today announced its support for NSERC funding for the group of Prof. B.M. Pinto at Simon Fraser University, Department of Chemistry, in a project titled “Molecular dynamics simulations of Ligand-Enzyme complexes for a novel target involved in cancer metabolism". The collaboration between Alectos Therapeutics and the Pinto group at SFU [...]

July 16th, 2012|Tags: , , , |

Alectos Supports NSERC Funding for Prof. L. Craig at SFU

April 30, 2012 – Alectos today announced its support for NSERC funding for the group of Prof. L. Craig at Simon Fraser University, Department of Molecular Biology and Biochemistry, in a project titled “Structural analysis of small molecule inhibitors of a novel target for the treatment of cancer". Compared to normal cells, cancer cells exhibit [...]

April 30th, 2012|Tags: , , , |

Alectos Supports NSERC Funding for Prof. R.A. Britton at SFU

Feb 1, 2012 – Alectos today announced its support for NSERC funding for the group of Prof. R.A. Britton at Simon Fraser University, Department of Chemistry, in a project titled “Synthesis of small molecule modulators of cancer metabolism". Cancer is a worldwide health problem and is the leading cause of death in Canada. Novel treatment [...]

February 1st, 2012|Tags: , , , |

Alectos Therapeutics Announces Collaboration with Merck to Develop Drugs for Alzheimer’s Disease

Collaboration Targets a Potential Non-Amyloid Approach to Treating Alzheimer’s Disease Vancouver, Canada (August 11, 2010) – Alectos Therapeutics Inc. today announced a research collaboration with Merck, headquartered in Whitehouse Station, N.J., to identify and develop compounds that modulate O-linked N-acetylglucosaminidase (O-GlcNAcase) an enzyme that is believed to be involved in the development of Alzheimer’s disease [...]

August 11th, 2010|Tags: , , |